FDA Inspection
DIAGASTDIAGAST – FDA Inspection, Feb 21, 2017
Record Details
This FDA Inspection record concerns DIAGAST, with an inspection on February 21, 2017, issued by the Center for Biologics Evaluation and Research, covering biologics.
View Company Profile
ID · 2956b5db-20d5-4502-9e06-ef04d8783a89
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1012901
- FDA center
- Biologics
- Project area
- Blood and Blood Products
- Outcome
- Form 483 issued
Other FDA inspections of DIAGAST
5| Date | Classification | Office | Project area |
|---|---|---|---|
| April 19, 2024 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| March 21, 2019 | Not classified | Office of Inspections and Investigations | |
| March 17, 2015 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| March 8, 2011 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| January 16, 2009 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
Other documents for DIAGAST
- FDA Inspection 1236304 - 2024-04-19
- FDA Inspection 1087957 - 2019-03-21
- FDA Inspection 927715 - 2015-03-17
- FDA Inspection 715544 - 2011-03-08
- FDA Inspection 594229 - 2009-01-16
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.